1569-16-0Relevant articles and documents
A mild synthesis of substituted 1,8-naphthyridines
Anderson, Edward C.,Sneddon, Helen F.,Hayes, Christopher J.
, p. 3050 - 3058 (2019)
A greener method for the synthesis of substituted 1,8-naphthyridines has been developed, which is supported by reaction metric analysis. Using 2-aminonicotinaldehyde as a starting material with a variety of carbonyl reaction partners, the Friedl?nder reac
Synthesis of 1,8-naphthyridine and BF2-based isomers and their application in fluorogenic sensing Cd2+
Liu, Xingjiang,Chen, Mingxing,Liu, Ziping,Yu, Mingming,Wei, Liuhe,Li, Zhanxian
, p. 658 - 663 (2014)
A series of isomers were synthesized and identified, two isomers of which were developed as the dual-channel fluorescent probe toward Cd2+. BF2 dissociates from the probe upon reaction with CdCl2, demonstrating a new approach for sensing Cd2+.
Olefin oxygenation by water on an iridium center
Ghatak, Tapas,Sarkar, Mithun,Dinda, Shrabani,Dutta, Indranil,Rahaman, S. M. Wahidur,Bera, Jitendra K.
, p. 6168 - 6171 (2015)
Oxygenation of 1,5-cyclooctadiene (COD) is achieved on an iridium center using water as a reagent. A hydrogen-bonding interaction with an unbound nitrogen atom of the naphthyridine-based ligand architecture promotes nucleophilic attack of water to the met
High-selectivity fibroblast growth factor receptor inhibitor and application
-
Paragraph 0087-0091, (2021/07/08)
The invention discloses a high-selectivity fibroblast growth factor receptor inhibitor and application, and particularly relates to a compound shown in a formula (I) or a pharmaceutically acceptable salt, a solvate, a geometric isomer, a stereoisomer, a tautomer and any mixture thereof. The compound shown in the formula (I) or the pharmaceutically acceptable salt, the solvate and the pharmaceutical composition thereof can be applied to prevention or treatment of diseases related to FGFR4 activity or overexpression, and can also be combined with other medicines to be used for treating various related diseases, especially for treating various cancers, wherein the cancers may be liver cancer, lung cancer, gastric cancer, breast cancer, ovarian cancer, prostate cancer, renal cell carcinoma, skin cancer, colon cancer, bile duct cancer, glioma or sarcoma.
ALPHAvBETA1 INTEGRIN ANTAGONISTS
-
Paragraph 0173, (2020/01/31)
The present disclosure provides pharmaceutical agents, including those of the formula: (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents are also provided. The compounds may be used for the inhibition or antagonism of integrins ανβ1 and/or α5β1. In some embodiments, the compounds provided herein exhibit reduced inhibitory or antagonistic activity of integrins ανβ3, ανβ5, ανβ6, ανβ8, and/or αIIbβ3.
Cooperative H2 Activation on Dicopper(I) Facilitated by Reversible Dearomatization of an “Expanded PNNP Pincer” Ligand
Kounalis, Errikos,Lutz, Martin,Broere, Dani?l L. J.
supporting information, p. 13280 - 13284 (2019/10/28)
A naphthyridine-derived expanded pincer ligand is described that can host two copper(I) centers. The proton-responsive ligand can undergo reversible partial and full dearomatization of the naphthyridine core, which enables cooperative activation of H2 giving an unusual butterfly-shaped Cu4H2 complex.
Transition metal-free α-methylation of 1,8-naphthyridine derivatives using DMSO as methylation reagent
Jiang, Shaohua,Yang, Zhihai,Guo, Ziyin,Li, Yibiao,Chen, Lu,Zhu, Zhongzhi,Chen, Xiuwen
, p. 7416 - 7424 (2019/08/15)
A practical approach to the direct α-methylation of 1,8-naphthyridines under mild reaction conditions has been developed using simple and readily available DMSO as a convenient and environmentally friendly carbon source. This method is transition metal-free and highly chemoselective, shows good functional group tolerance, and uses DMSO as a methyl source, providing efficient and rapid access to an important compound class, 2-methyl-1,8-naphthyridines.
PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS
-
Page/Page column 39, (2019/05/30)
The disclosure relates to compounds of formula I: Formula I which inhibit αv-containing integrins, and includes pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders.
Diruthenium complexes with a 1,8-Naphthyridine-based Bis(silyl) supporting ligand: Synthesis and structures of complexes containing RuII2(μ-H)2 and RuI2 cores
Kusuma, Indra,Komuro, Takashi,Tobita, Hiromi
, p. 400 - 403 (2018/03/27)
We designed a novel naphthyridine-based supporting ligand involving two silyl coordinating moieties at 2,7-positions, t-BuNBSi, for the synthesis of dinuclear metal complexes. Reaction of a ligand precursor t-BuNBSi(H)2 (1) with Ru3(CO)12 gave a di-μ-hydridodiruthenium(II,II) complex (t-BuNBSi)Ru2(μ-H)2(CO)4 (2). Photoirradiation to 2 resulted in the formation of a diruthenium(I,I) complex (t-BuNBSi)Ru2(CO)6 (3). The SiRuRuSi linkage of 2 takes a zigzag arrangement, whereas that of 3 adopts a roughly linear one.
INTEGRIN ANTAGONISTS
-
Page/Page column 57, (2018/08/03)
The present disclosure provides pharmaceutical agents, including those of the formula:(I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Meth
